- Stock: In Stock
Available Options
Description
HER3 ELISA Kit
Catalog Number: HER3-01-1220
Size: 1 plate (96 wells)
HER3 ELISA Kit is a sandwich enzyme-linked immunoassay for
the quantitative determination of HER3 with high sensitivity and specificity in
serum or plasma.
Kit
Performance
- Sensitivity: 50 pg/mL
- Assay Range: 50 – 1000 pg/mL
- Cross-reactivity: There is no
cross reaction with native immunoglobulins
- Recovery rate: 80 – 120% with
normal human serum or plasma samples with known concentrations.
- Precision
(CV
(%) = SD/mean X 100)
- Intra-Assay: CV < 20%
- Inter-Assay: CV < 20%
Materials
Supplied
List
of component
|
Components |
Quantity |
|
High binding Plate |
1 plate |
|
HER3 |
1 µg |
|
10x Capture |
700 µL |
|
10x Detection |
700 µL |
|
1x Streptavidin (HRP) (Avoid
light) |
12 mL |
|
1x Plate Coating Buffer |
15 mL |
|
1x Blocking Buffer |
15 mL |
|
2x Assay Diluent |
30 mL |
|
1x TMB Substrate (Avoid light) |
12 mL |
|
1x Stop Solution |
12 mL |
Storage
Instruction
The
components arrive with ice pack, and must immediately be stored at 2-8°C. The
kit components are stable at the date specified in CoA.
Supplementary
information
HER3
(Human Epidermal Growth Factor Receptor 3), also known as ERBB3, is a member of
the ERBB receptor tyrosine kinase family. Unlike other ERBB family members,
HER3 has very weak intrinsic kinase activity. As a result, it cannot
efficiently phosphorylate itself and instead relies on forming heterodimers
with other ERBB receptors, most commonly HER2.
The
HER2–HER3 heterodimer is considered one of the most potent signaling complexes
in the ERBB network. HER3 contains multiple docking sites for the PI3K
signaling pathway, allowing strong activation of the PI3K–AKT pathway, which
promotes cell survival and resistance to apoptosis.
In
cancer, HER3 itself is rarely amplified, but it often acts as a critical
signaling partner for HER2 or EGFR-driven tumors. Increased HER3 expression or
activation has been observed in several cancers, including breast, lung,
ovarian, and gastric cancers.